• According to Transparency Market Research’s latest report on the global Alpha 1 Antitrypsin Deficiency Treatment market for the historical period 2017–2018 and forecast period 2019–2027, rising incidence & prevalence of respiratory diseases and growing awareness for alpha 1 antitrypsin (AAT) deficiency are projected to drive the global Alpha 1 Antitrypsin Deficiency Treatment market during the forecast period
  • According to the report, the global Alpha 1 Antitrypsin Deficiency Treatment market was valued at US$ 1.4 Bn in 2018 and is anticipated to grow at a CAGR of 10.1% from 2019 to 2027
new fa global alpha 1 antitrypsin deficiency treatment market

To know the scope of our report Get a Sample on Alpha 1 Antitrypsin Deficiency Treatment Market

Rising incidence and prevalence of respiratory diseases across the globe: Key Driver

  • High prevalence and rise in incidence rate of respiratory diseases across the globe is a key factor driving the global Alpha 1 Antitrypsin deficiency treatment market.
  • For instance, according the World Health Organization (WHO), every year, around 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die due to this disease worldwide.
  • Furthermore, awareness for AAT deficiency in developing regions is also fuelling the growth of global Alpha 1 Antitrypsin deficiency treatment market.
  • Moreover growing government initiatives for increasing blood and plasma products and rise in prescription of combination therapies are also contributed for the growth of global market.

Get a glimpse of the in-depth analysis through our Report Brochure

Side effects and complications related to Alpha 1 Antitrypsin Deficiency Treatment products hamper the market growth

  • Treatment of Alpha 1 Antitrypsin deficiency may cause some serious side effects such as back pain, chest pain, rhinorrhea, sinusitis which can hamper the market growth.
  • High cost of therapy and lesser diagnosis rate for the disease are also some of the factors which can adversely affect the market growth.  

Global Alpha 1 Antitrypsin Deficiency Treatment Market: North America dominated the global market

  • On the basis of region, the Alpha 1 Antitrypsin Deficiency Treatment market is segmented as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
  • North America region dominated the global market owing to higher prevalence of respiratory diseases in the region, higher R&D investment funding by major companies, and better diagnosis rate for AAT deficiency.
  • However, Europe region is considered as the most lucrative market during the forecast period from 2019 to 2027. The growth is mainly ascribed to factors such as growing aging population which is more prone to respiratory diseases, growing awareness & product demand of Alpha 1 Antitrypsin Deficiency Treatment, and rising research & development for respiratory disease treatment.

Expanding operations in future? To get the perfect launch ask for a custom report 

Global Alpha 1 Antitrypsin Deficiency Treatment Market: Competitive Landscape

  • This report profiles major players in the global Alpha 1 Antitrypsin deficiency treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global Alpha 1 Antitrypsin Deficiency Treatment market is highly consolidated, with a few global players accounting for a major share in market.
  • Leading players operating in the global Alpha 1 Antitrypsin Deficiency Treatment market are
    • Grifols, S.A
    • Takeda Pharmaceutical Company Limited
    • CSL Behring
    • Kamada Pharmaceuticals
    • GlaxoSmithKline Plc.
    • AstraZeneca
    • Boehringer Ingelheim GmbH
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • LFB Biomedicaments S.A.?

Global Alpha 1 Antitrypsin Deficiency Treatment Market: Key Developments

Key players in the global Alpha 1 Antitrypsin Deficiency Treatment market are engaged in regulatory approvals, new product development, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global Alpha 1 Antitrypsin Deficiency Treatment market. A few expansion strategies adopted by players operating in the global Alpha 1 Antitrypsin Deficiency Treatment market are:

  • In September 2019, Kamada Ltd. has extended strategic supply agreement with Takeda for GLASSIA [Alpha1-Proteinase Inhibitor (Human)].  This will help company to produce GLASSIA for Takeda through 2021.
  • In April 2019, U.S. FDA has approved CSL Behring product ZEMAIRA [Alpha1-Proteinase Inhibitor (Human)] 4- and 5-gram vial sizes in the U.S. for the treatment of Alpha 1 Antitrypsin Deficiency (Alpha 1).

The report on the global Alpha 1 Antitrypsin Deficiency Treatment market discussed individual strategies, followed by company profiles of manufacturers of Alpha 1 Antitrypsin Deficiency Treatment. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global Alpha 1 Antitrypsin Deficiency Treatment market.

TMR’s report on the global Alpha 1 Antitrypsin deficiency treatment market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators of the market during the forecast period from 2019 to 2027. The report provides revenue of the global Alpha 1 Antitrypsin deficiency treatment market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global Alpha 1 Antitrypsin deficiency treatment market during the forecast period.

The report has been prepared after an extensive primary and secondary research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion-makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global Alpha 1 Antitrypsin deficiency treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, company presentations, sales data, and trade associations. Analysts have employed a combination of top-down and bottom-up approaches to study various phenomenon in the global Alpha 1 Antitrypsin deficiency treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Furthermore, the report sheds light on the changing competitive dynamics in the global Alpha 1 Antitrypsin deficiency treatment market. These indices serve as valuable tools for existing market players as well as for entities interested in entering the global Alpha 1 Antitrypsin deficiency treatment market.

The report delves into the competitive landscape of the global Alpha 1 Antitrypsin deficiency treatment market. Key players operating in the global Alpha 1 Antitrypsin deficiency treatment market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players in the global Alpha 1 Antitrypsin Deficiency Treatment market that have been profiled in this report.

Key Questions Answered in Global Alpha 1 Antitrypsin Deficiency Treatment market Report

  • What is the scope of growth of product companies in the global Alpha 1 Antitrypsin deficiency treatment market?
  • What will be the Y-o-Y growth of the global Alpha 1 Antitrypsin Deficiency Treatment market between 2019 and 2027?
  • What is the influence of changing trends in pipeline products on the global Alpha 1 Antitrypsin deficiency treatment market?
  • Will North America continue to be the most profitable market for Alpha 1 Antitrypsin Deficiency Treatment providers?
  • Which factors are anticipated to hamper the growth of the global Alpha 1 Antitrypsin Deficiency Treatment market during the forecast period?
  • Which are the leading companies in the global Alpha 1 Antitrypsin Deficiency Treatment market?

Research Methodology

A unique research methodology has been utilized by TMR to conduct comprehensive research on the growth of the global Alpha 1 Antitrypsin deficiency treatment market and arrive at conclusions on its growth prospects. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary methods referred to by analysts during the production of the global Alpha 1 Antitrypsin deficiency treatment market report include statistics from company annual reports, SEC filings, company websites, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of TMR’s study on the Alpha 1 Antitrypsin deficiency treatment market as primary methods.

These primary and secondary methods have provided exclusive information during interviews, which serves as a validation from the Alpha 1 Antitrypsin deficiency treatment market leaders. Access to an extensive internal repository and external proprietary databases enabled this report to address specific details and questions about the global Alpha 1 Antitrypsin deficiency treatment market with accuracy. The study also uses the top-down approach to assess the revenues for each segment and the bottom-up approach to counter-validate them. This has helped in reaching TMR’s estimates on future prospects of the global Alpha 1 Antitrypsin deficiency treatment market more reliably and accurately.

Regional Segmentation of Alpha 1 Antitrypsin Deficiency Treatment market

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

The Global Alpha-1 Antitrypsin Deficiency Treatment Market has been segmented as follows:

by Treatment Type

  • Augmentation Therapy
    • Aralast
    • Prolastin
    • Zemaira/Respreeza
    • Glassia
  • Bronchodilator
  • Corticosteroids
  • Oxygen Therapy
  • Others

by Route of Administration

  • Parenteral
  • Inhalations
  • Oral

by End-User

  • Specialty Clinics
  • Hospitals
  • Pharmacies

by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

REQUEST CUSTOMIZATION

Alpha 1 Antitrypsin Deficiency Treatment Market

Buy Now